Haoming Qiu1, Michael J Moravan1, Michael T Milano1, Kenneth Y Usuki1, Alan W Katz2. 1. Department of Radiation Oncology, University of Rochester Medical Center, 601 Elmwood Avenue, Box 647, Rochester, NY, 14642, USA. 2. Department of Radiation Oncology, University of Rochester Medical Center, 601 Elmwood Avenue, Box 647, Rochester, NY, 14642, USA. alan_katz@urmc.rochester.edu.
Abstract
PURPOSE: The study aimed to evaluate stereotactic body radiotherapy (SBRT) for hepatocellular carcinoma (HCC) in patients not eligible for liver transplant (LT). METHODS: We retrospectively identified transplant-ineligible HCC patients treated with SBRT to the liver between 2004 and 2013. Our primary endpoint was overall survival (OS). We also report treatment toxicities using CTCAE 3.0, radiographic response, and patterns of failure. RESULTS: We identified 93 patients with median age at SBRT of 65.8 years. Forty-six percent were classified as Child-Pugh B or C and 85% had an Eastern Cooperative Oncology Group performance status of 1-2. After SBRT, 86% of patients experienced no or mild treatment-related adverse events. Only 8% of patients experienced grade 3 and 2% of patients experienced grade 4 adverse events. Overall radiographic response was complete in 1.2%, partial in 35.4%, stable in 43.9%, and progressive disease in 19.5%. Median OS was 8.8 months with 1-, 2-, and 3-year OS rates of 38.0, 29.8 and 21.2%, respectively. The Cancer of the Liver Italian Program (CLIP) score was found to strongly correlate with survival. Median OS for patients with CLIP scores of 0, 1, 2, and 3 was 21.1, 8.5, 5.1, and 7.1 months, respectively (p = 0.003). CONCLUSION: Our series demonstrates that SBRT is generally safe for HCC patients, even those with advanced liver failure. Although survival is generally poor, we were able to identify a group of patients with good liver function and early tumor stage who can achieve median OS of close to 2 years with SBRT.
PURPOSE: The study aimed to evaluate stereotactic body radiotherapy (SBRT) for hepatocellular carcinoma (HCC) in patients not eligible for liver transplant (LT). METHODS: We retrospectively identified transplant-ineligible HCCpatients treated with SBRT to the liver between 2004 and 2013. Our primary endpoint was overall survival (OS). We also report treatment toxicities using CTCAE 3.0, radiographic response, and patterns of failure. RESULTS: We identified 93 patients with median age at SBRT of 65.8 years. Forty-six percent were classified as Child-Pugh B or C and 85% had an Eastern Cooperative Oncology Group performance status of 1-2. After SBRT, 86% of patients experienced no or mild treatment-related adverse events. Only 8% of patients experienced grade 3 and 2% of patients experienced grade 4 adverse events. Overall radiographic response was complete in 1.2%, partial in 35.4%, stable in 43.9%, and progressive disease in 19.5%. Median OS was 8.8 months with 1-, 2-, and 3-year OS rates of 38.0, 29.8 and 21.2%, respectively. The Cancer of the Liver Italian Program (CLIP) score was found to strongly correlate with survival. Median OS for patients with CLIP scores of 0, 1, 2, and 3 was 21.1, 8.5, 5.1, and 7.1 months, respectively (p = 0.003). CONCLUSION: Our series demonstrates that SBRT is generally safe for HCCpatients, even those with advanced liver failure. Although survival is generally poor, we were able to identify a group of patients with good liver function and early tumor stage who can achieve median OS of close to 2 years with SBRT.
Entities:
Keywords:
Child-Pugh B and C; Hepatocellular carcinoma; Non-transplant candidates; SBRT
Authors: Alexis Bujold; Christine A Massey; John J Kim; James Brierley; Charles Cho; Rebecca K S Wong; Rob E Dinniwell; Zahra Kassam; Jolie Ringash; Bernard Cummings; Jenna Sykes; Morris Sherman; Jennifer J Knox; Laura A Dawson Journal: J Clin Oncol Date: 2013-04-01 Impact factor: 44.544
Authors: Shaelyn Culleton; Haiyan Jiang; Carol R Haddad; John Kim; Jim Brierley; Anthony Brade; Jolie Ringash; Laura A Dawson Journal: Radiother Oncol Date: 2014-06-03 Impact factor: 6.280
Authors: Tracy R Price; Susan M Perkins; Kumar Sandrasegaran; Mark A Henderson; Mary A Maluccio; Jennifer E Zook; A Joseph Tector; Rodrigo M Vianna; Peter A S Johnstone; Higinia R Cardenes Journal: Cancer Date: 2011-10-24 Impact factor: 6.860
Authors: Alan W Katz; Sheema Chawla; Zhenhong Qu; Randeep Kashyap; Michael T Milano; Aram F Hezel Journal: Int J Radiat Oncol Biol Phys Date: 2011-12-13 Impact factor: 7.038
Authors: Won Il Jang; Mi-Sook Kim; Sun Hyun Bae; Chul Koo Cho; Hyung Jun Yoo; Young Seok Seo; Jin-Kyu Kang; So Young Kim; Dong Han Lee; Chul Ju Han; Jin Kim; Su Cheol Park; Sang Bum Kim; Eung-Ho Cho; Young Han Kim Journal: Radiat Oncol Date: 2013-10-27 Impact factor: 3.481
Authors: Peter Lee; Yunsheng Ma; Isabel Zacharias; Adel Bozorgzadeh; Sean Wilson; Kim Foley; Paul Rava; Mark Masciocchi; Linda Ding; Jacob Bledsoe; Thomas J Fitzgerald; Shirin Sioshansi Journal: Adv Radiat Oncol Date: 2020-04-09
Authors: Dominik Bettinger; David J Pinato; Michael Schultheiss; Rohini Sharma; Lorenza Rimassa; Tiziana Pressiani; Michela E Burlone; Mario Pirisi; Masatoshi Kudo; Joong Won Park; Nico Buettner; Christoph Neumann-Haefelin; Tobias Boettler; Nasrin Abbasi-Senger; Horst Alheit; Wolfgang Baus; Oliver Blanck; Sabine Gerum; Mathias Guckenberger; Daniel Habermehl; Christian Ostheimer; Oliver Riesterer; Jörg Tamihardja; Anca-Ligia Grosu; Robert Thimme; Thomas Baptist Brunner; Eleni Gkika Journal: Liver Cancer Date: 2018-07-12 Impact factor: 11.740
Authors: Dominik Bettinger; Eleni Gkika; Michael Schultheiss; Nicolas Glaser; Sophie Lange; Lars Maruschke; Nico Buettner; Simon Kirste; Ursula Nestle; Anca-Ligia Grosu; Robert Thimme; Thomas B Brunner Journal: BMC Cancer Date: 2018-08-09 Impact factor: 4.430
Authors: Kimberly M Arnold; Nicole J Flynn; Adam Raben; Lindsay Romak; Yan Yu; Adam P Dicker; Firas Mourtada; Jennifer Sims-Mourtada Journal: Cancer Growth Metastasis Date: 2018-03-09